First-Line Cabazitaxel Proves Beneficial in Patients With Metastatic Prostate Cancer

This study tested first-line treatment with cabazitaxel vs hormonal therapy in patients with metastatic castration-resistant prostate cancer with poor prognosis.

Source: CancerNetwork - June 1, 2019 Category: Cancer & Oncology Authors: Lauren M. Dembeck Source Type: news